Pfizer dismantled the Tepid Big Pharma Q2 window, raising his profitables away from VyndaQel (TAFAMIDIS) and ELIQUIS, APIXABAN, among other things.
The company’s quarterly revenues amounted to $ 14.7 billion, an increase of 10 % of the same period in 2024. The company also told modified profits of 0.78 dollars per share, easily of $ 0.58 per share by analysts who receive it in facts.
While the pharmaceutical maker reaffirmed its revenue for 2025, at a value of 61 billion dollars to 64 billion dollars, it raised the profit forecast for the entire 2025. PFIZER now expects to earn $ 2.90 to $ 3.10 per share, compared to its previous expectations from $ 2.80 to $ 3.00 for this year.
Pfizer stocks increased by 3 % to $ 24.27 in the open market on August 8, compared to the market closure the day before. The company has a market value of 138.9 billion dollars.
It represents a strong transformation of CEO Dr. Albert Burla, who was in The risk of losing his leadership position Nine months ago, amid pressure from the activists of the real investor.
“Pfizer had another powerful quarter of the concentrated implementation, and we are happy to advance in the progress of our search and development pipeline, prompting our commercial performance and expanding our margin. We continue to strengthen our company for the future, and we are confident of our ability to create the value of more value to our patients,” Purla said.
The updated expectations for 2025 are also a $ 1.35 billion fees for one time related to a license agreement with 3SBIO, with permission to a partnership created in May 2025. The charge will be registered in the third quarter of 2025 with a negative impact of $ 0.20 per share.
The strong Q2 results were fueled by a variety of medicines in the Pfizer portfolio, which represents the durability of the company’s commercial offers. VyndaQel sales increased by 21 % to the net global sales of $ 1.6 billion, while ELIQUIS is the thinner blood has been born on the 2 billion dollar sign for a quarter.
Pfizer objected to the decrease in demand Covid-19 by reporting sales growth for virus-related products. Comirnaty vaccine sales increased 95 % while antiviral drugs grew 71 %. Together, they brought 808 million dollars to the company.
In addition to Covid-19, PFIZER has a long list of vaccines in the market for the virus of the respiratory system (RSV), pneumococci diseases, and Lyme disease, among other things. Together, vaccine sales make up about 20 % of Fayzer’s revenues. Al Ain was the document on the results of the Q2 for companies that have a vaccine specialization amid changes to the American organizational environment under the Minister of Health RFK JR.
https://media.zenfs.com/en/pharmaceutical_technology_376/3c73fdf1f024c32205dd8e6a8b7639a2
Source link